To investigate the risk of thromboembolic disease (TED) in men with prostate cancer (PCa) on androgen deprivation therapy (ADT) while accounting for known TED risk factors.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
TED risk was assessed for 42,263 PCa men on ADT compared to a matched, PCa-free cohort of 190,930 men.
Associations between ADT and deep venous thrombosis (DVT) or pulmonary embolism (PE) were analysed using multivariate Cox proportional hazard regression models. Previous PCa-related surgeries and the following proxies for disease progression: transurethral resection of the prostate, palliative radiotherapy and nephrostomy, were accounted for.
Between 1997-2013, 11,242 PCa men received anti-androgen (AA) monotherapy, 26,959 gonadotropin-releasing hormone (GnRH) agonists, 1,091 combined androgen blockade, and 3,789 underwent orchiectomy. When accounting for previous surgeries and proxies of disease progression, GnRH agonist users and surgically castrated men were at increased TED risk versus the comparison cohort, HR: 1. 67 (95% CI: 1. 40-1. 98) and 1. 61 (95% CI: 1. 15-2. 28), respectively. Men on AA monotherapy were at decreased risk, HR for DVT: 0. 49 (95% CI: 0. 33-0. 74). TED risk was highest among those who switched from AA to GnRH agonists, PE HR: 2. 55 (95% CI: 1. 76-3. 70). This increased from 2. 52 (95% CI: 1. 54-4. 12) in year one, to 4. 05 (95% CI: 2. 51-6. 55) in year two.
TED incidence among men on ADT increased with the duration of therapy and risk was highest for those who switched regimen, thus implicating roles for disease progression as well as ADT in propagating TED risk. Nonetheless, these findings support that only men with a relevant indication should receive systemic ADT. This article is protected by copyright. All rights reserved.
BJU international. 2015 Oct 24 [Epub ahead of print]
Sean O'Farrell, Karin Sandström, Hans Garmo, Pär Stattin, Lars Holmberg, Jan Adolfsson, Mieke Van Hemelrijck
King's College London, Division of Cancer Studies, Cancer Epidemiology Group, London. , King's College London, Division of Cancer Studies, Cancer Epidemiology Group, London. , King's College London, Division of Cancer Studies, Cancer Epidemiology Group, London. , Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. , King's College London, Division of Cancer Studies, Cancer Epidemiology Group, London. , Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Sweden. , King's College London, Division of Cancer Studies, Cancer Epidemiology Group, London.